Frontal Fibrosing Alopecia GWAS Implicates Risk Loci with Links to Immune System
Together with gene expression results from affected tissue, the findings suggest that drugs such as JAK inhibitors may be effective for the treatment of FFA.
The drug is designed to silence connective tissue growth factor, which is implicated in scarring and fibrosis.
RXi Pharmaceuticals said this week that it has signed a deal giving the European Union distribution rights to its investigational anti-scarring drug RXI-109 to UK-based Ethicor.
This article has been updated to include details about RXi's third quarter financial results. RXi Pharmaceuticals this week announced that it has begun dosing patients in a phase II trial of its investigational anti-scarring drug RXI-109.
RXi Pharmaceuticals this week released data from a phase I trial of its dermal anti-scarring drug RXI-109, showing that the compound was safe and well-tolerated.
Jun 6, 2013
Apr 4, 2013
Dec 6, 2012
Nov 15, 2012
Sep 27, 2012
Jun 28, 2012
May 31, 2012
May 10, 2012
Feb 9, 2012
Feb 3, 2011
Jun 17, 2010